Generation of individualized cancer immuno-therapy independent of HLA-haplotypes

2017 Fiscal Year Final Research Report

• Project/Area Number: 15H04308
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Tumor therapeutics
• Research Institution: University of Toyama
• Principal Investigator: Kishi Hiroyuki 富山大学, 大学院医学薬学研究部(医学), 准教授 (60186210)
• Co-Investigator(Kenkyū-buntansha): 小澤 龍彦 富山大学, 大学院医学薬学研究部(医学), 助教 (10432105) ; 村口 篤 富山大学, 大学院医学薬学研究部(医学), 名誉教授 (20174287)
• Co-Investigator(Renkei-kenkyūsha): HAMANA Hiroshi 富山大学, 大学院医学薬学研究部(医学), 客員准教授 (90551549) ; NISHIKAWA Hiroyoshi 国立がん研究センター, 先端医療開発センター, 免疫TR分野長 (10444431)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: Tumor / T cells / T cell receptor

Outline of Final Research Achievements

T cells play important roles to suppress cancer generation in vivo. Recently, cancer therapy using T cells has been studied. T cells recognize the complex of cancer antigens and HLA molecules on cancer cells and kill them. The structure of HLA molecules are different in individual persons and T cells from a person whose HLA haplotype is different from a patient's HLA haplotype can not be used for the treatment of the patient. Major Japanese populations have HLA-A2 or A24 molecules. Thus, T cells recognizing cancer antigens in the context of HLA-A2 or A24 are studied, but those recognizing other HLA molecules are not. In this study, we have developed the method to find cancer-specific T cells independently of HLA haplotypes.

Free Research Field

Cancer Immunology